Bio-Techne (TECH) Stock Could Be 10.4% Undervalued After Refeyn Collaboration

Bio-Techne (TECH) stock has been in focus after the company partnered with Refeyn on a four hour workflow that links charge heterogeneity, molecular weight, and aggregation in bispecific antibodies and biosimilars at single molecule resolution.

See our latest analysis for Bio-Techne.

Alongside the Refeyn partnership, Bio-Techne’s recent share price return of 23.79% over 30 days contrasts with a year to date share price decline of 7.80%, while the 1 year total shareholder return of 10.38% sits against a 5 year total shareholder return decline of 49.38%. This suggests short term momentum has picked up after a weaker multi year stretch.

If this kind of biotech tools story interests you, it may be worth widening your search through our screener of 40 healthcare AI stocks.

With Bio-Techne trading at US$55.00 against an average analyst price target of US$61.31 and one estimate of fair value near US$61.42, the question is simple: is there real upside left here or is the market already pricing in future growth?

Most Popular Narrative: 10.4% Undervalued

With Bio-Techne stock at $55.00 against a narrative fair value of $61.42, the most followed story in the market argues the current price sits below those assumptions.

The company's shift in portfolio focus, highlighted by the divestiture of Exosome Diagnostics, allows redeployment of capital and resources toward higher margin core business segments and growth pillars, supporting both immediate operating margin improvement (expected 100–200 basis point expansion) and higher future earnings. Accelerated innovation and product launches in automated proteomic instrumentation (for example, Leo Simple Western and Maurice) and digital platforms are driving high margin, high throughput product adoption, increasingly embedding the company's solutions in regulated pharma manufacturing workflows.

Read the complete narrative.

Want to see what sits behind that fair value for Bio-Techne? The narrative leans heavily on compounding earnings, improving profitability, and a rich future earnings multiple that the market is not fully reflecting yet.

Result: Fair Value of $61.42 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, there are still clear pressure points for the Bio-Techne story, including weaker biotech funding and potential tariff or pricing changes that could weigh on customer demand.

Find out about the key risks to this Bio-Techne narrative.

Another View: Bio-Techne stock through earnings multiples

The fair value story for Bio-Techne hinges on future earnings, but current pricing tells a different tale. At a P/E of 78.6x, compared with 64.6x for peers and 34.9x for the wider Life Sciences industry, and a fair ratio of 24.6x, the stock screens as expensive. This raises the question of whether this premium aligns with your investment approach.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of optimism and concern around Bio-Techne leaves you undecided, now is a good time to review the numbers yourself and decide where you stand, starting with 1 key reward and 1 important warning sign

Looking for more investment ideas beyond Bio-Techne?

If the Bio-Techne story has sharpened your focus, do not stop here. Broadening your search now could reveal opportunities that fit your style even better.

• Target potential mispricings by scanning for companies that look attractively valued using the 48 high quality undervalued stocks.
• Build a steadier income stream by reviewing candidates in the 8 dividend fortresses.
• Prioritise resilience by focusing on businesses highlighted in the 65 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com